Our Team

COMPLETE BIOS AVAILABLE UPON REQUEST

Christopher Fey, Co-Founder & Co-CEO Chris.Fey@USPM.global

Chris Fey has a long career in health care and as an entrepreneur, particularly in the fields of managed care, blood products, vaccines. In the pharma industry, he worked on multiple projects for Alpha Therapeutics Corp., Merck, North American Biologicals and Green Cross Corp. He founded HealthCare USA, Inc. (a Medicaid, Medicare, commercial, multi-state HMO), which was sold to publicly-held Coventry Health Care. He also founded a nationwide prevention services for employers, U.S. Preventive Medicine, which won multiple awards such as recognition for its mobile app. He served on the Wall Street Journal “CEO Council of 100” and has spoken internationally on current health care topics.

Frederick Fey, Co-Founder & Co-CEO Fred.Fey@USPM.global

Fred Fey is a seasoned entrepreneur and consultant with deep experience in creating and leading health care companies, including highly successful Medicaid managed care startups in major markets. He specializes in strategic and business development, product development and capital fundraising and as well as developing management services organizations. Fey founded or co-founded three Medicaid health plans that were profitable due in part to innovative strategies involving key partnerships, unique benefits, and the desire to improve the lives of members. He also HealthScreen America, a retail screening center, for which he and his brother Chris raised $18 million in private placements and secured commitments for an additional $35 million.

SATYA NARAYAN, Ph.D., Chief Science Officer

Satya Narayan, who holds several patents, is a Professor in the Department of Anatomy and Cell Biology at the University of Florida, and has an extensive background in the development of structure-based therapeutics and their application in preclinical studies of cancer.

He has provided experimental basis describing the role of adenomatous polyposis coli (APC) and base excision repair (BER) pathway in the transformation of cigarette smoke condensate, a surrogate of cigarette smoke, induced normal breast epithelial cells in vitro and in vivo assays. Dr. Narayan’s research group also has synthesized a Biisoquinoline-derivative, DH20931, a small molecule that stimulates the activity of ceramide synthase 2 (CerS2) and the synthesis of ceramides with very long chain fatty acids and induces alone or with doxorubicin-mediated sensitization of breast cancer cells.

Based upon a high-throughput structure based molecular docking strategy, his research team identified a group of highly specific small molecule inhibitors that interact with DNA polymerase β (Pol-β) and flap endonuclease 1 (FEN1) and inhibit colorectal cancer (CRC) growth in vitro and in vivo models.

Dr. Narayan identified a novel phosphatase 2A (PP2A) activator that in combination with 5-FU inhibits the growth of CRC FOLFOX-resistant CRC cells in vitro and in vivo patients-derived tumor xenograft (PDX) models.

STEVEN CHAMBERLAIN, General Counsel

Steve Chamberlain is a tax attorney whose focuses on business transactions, including mergers and acquisitions, issuance of securities, and stockholder litigation. He has formed hundreds of corporations, LLCs, partnerships and trusts. He has a degree from MIT and was an economist with Nixon’s Cost of Living Council before getting his JD and Masters of Taxation degrees from the University of Florida. He has been a long-time member of the Executive Council of the Tax Section, where he founded the Bankruptcy/Tax Committee. He is widely published in legal journals, has presented numerous continuing legal education lectures, and the first Florida attorney to win an award of attorney’s fees from the United States Tax Court.